BioVaxys Technology Corp, a Canadian biotechnology firm, has been making significant strides in the realm of vaccine and immunotherapy development. Headquartered in Vancouver, British Columbia, the company has been a key player in life sciences research and development since its incorporation in 2001. With a primary listing on the Canadian National Stock Exchange, BioVaxys has demonstrated a commitment to addressing global health challenges, particularly in the domains of infectious diseases and cancer.
As of May 21, 2026, BioVaxys’s stock closed at CAD 0.07, reflecting a notable fluctuation over the past year, with a 52-week high of CAD 0.3 on October 14, 2025, and a low of CAD 0.03 on April 12, 2026. The company’s market capitalization stands at CAD 2,845,792, with a price-to-earnings ratio of -0.461, indicating ongoing investment in research and development over immediate profitability.
Central to BioVaxys’s portfolio is VaxMite, an innovative vaccine targeting Plasmodium falciparum, the most lethal form of malaria. This development underscores the company’s mission to revolutionize the prevention and treatment of infectious diseases. VaxMite represents a significant advancement in the fight against malaria, a disease that continues to pose a substantial global health burden.
In addition to its work on malaria, BioVaxys is exploring the potential of its technology platform across various medical and healthcare applications. The company’s focus on cancer immunotherapy highlights its dedication to pioneering new treatment modalities. By leveraging cutting-edge research, BioVaxys aims to develop novel immunotherapy approaches that could transform cancer treatment paradigms.
BioVaxys’s strategic initiatives reflect a broader commitment to innovation and global health improvement. The company’s efforts in vaccine development and immunotherapy are poised to make substantial contributions to public health, addressing some of the most pressing medical challenges of our time. As BioVaxys continues to expand its research and development activities, it remains at the forefront of biotechnological advancements, with a clear vision of transforming healthcare outcomes worldwide.
